Bulletin
Investor Alert

Deciphera Pharmaceuticals Inc.

NAS: DCPH

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

May 18, 2022, 6:43 p.m.

/zigman2/quotes/203556943/composite

$

10.40

Change

-0.52 -4.67%

Volume

Volume 19,531

Quotes are delayed by 20 min

/zigman2/quotes/203556943/composite

Today's close

$ 11.43

$ 10.91

Change

-0.52 -4.55%

Day low

Day high

$10.71

$11.22

Open

52 week low

52 week high

$6.51

$38.91

Open

Patricia L. Allen

Ms. Patricia L. Allen, CPA, is a Chief Financial Officer at Vividion Therapeutics, Inc., an Independent Director at Yumanity Therapeutics, Inc. and an Independent Director at Deciphera Pharmaceuticals, Inc. She is on the Board of Directors at Yumanity Therapeutics, Inc., SwanBio Therapeutics, Inc., Anokion SA, Inversago Pharma, Inc., Deciphera Pharmaceuticals, Inc., Deciphera Pharmaceuticals LLC and Kanyos Bio, Inc. Ms. Allen was previously employed as a Chief Financial & Accounting Officer by Zafgen, Inc., a Treasurer & Vice President-Finance by Alnylam Pharmaceuticals, Inc., a Finance Director by Alkermes, Inc., and an Audit Manager by Deloitte & Touche LLP. She also served on the board at Yumanity, Inc. She received her undergraduate degree from Bryant University.

Transactions

Date Shares Transaction Value
06/05/2020 5,635   Disposition at $55.9 per share. 314,997
06/05/2020 5,635   Derivative/Non-derivative trans. at $25.73 per share. 144,988
06/03/2020 6,365   Disposition at $59.14 per share. 376,427
06/03/2020 6,365   Derivative/Non-derivative trans. at $25.73 per share. 163,771
01/24/2020 700   Disposition at $67.36 per share. 47,152
01/24/2020 6,496   Disposition at $66.55 per share. 432,309
01/24/2020 17,804   Disposition at $65.93 per share. 1,173,818
01/24/2020 25,000   Derivative/Non-derivative trans. at $3.95 per share. 98,750

Officers and Executives

Mr. Steven L. Hoerter
President & Chief Executive Officer
Mr. Thomas P. Kelly
Chief Financial Officer, Treasurer & Executive VP
Dr. Matthew L. Sherman
Chief Medical Officer & Executive Vice President
Dr. Rodrigo Ruiz Soto
Senior Vice President-Clinical Development
Dr. Daniel L. Flynn
Chief Scientific Officer & Executive VP
Dr. Stephen B. Ruddy
Chief Technical Officer & SVP
Mr. Daniel C. Martin
Chief Commercial Officer & SVP
Mr. Jeffrey M. Held
General Counsel & Senior Vice President
Mr. Jama Pitman
Vice President-Regulatory & Quality Assurance
Dr. James A. Bristol
Chairman
Dr. Susan L. Kelley
Independent Director
Mr. Ron Squarer
Independent Director
Mr. Franklin S. Friedman
Independent Director
Ms. Patricia L. Allen
Independent Director
Dr. Edward J. Benz
Independent Director
Mr. John R. Martin
Independent Director
Mr. Dennis L. Walsh
Independent Director
Link to MarketWatch's Slice.